These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 33051668)

  • 1. Phase I studies of darinaparsin in patients with relapsed or refractory peripheral T-cell lymphoma: a pooled analysis of two phase I studies conducted in Japan and Korea.
    Ogura M; Kim WS; Uchida T; Uike N; Suehiro Y; Ishizawa K; Nagai H; Nagahama F; Sonehara Y; Tobinai K
    Jpn J Clin Oncol; 2021 Feb; 51(2):218-227. PubMed ID: 33051668
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Darinaparsin in patients with relapsed or refractory peripheral T-cell lymphoma: results of an Asian phase 2 study.
    Kim WS; Fukuhara N; Yoon DH; Yamamoto K; Uchida T; Negoro E; Izutsu K; Terui Y; Nakajima H; Ando K; Suehiro Y; Kang HJ; Ko PS; Nagahama F; Sonehara Y; Nagai H; Tien HF; Kwong YL; Tobinai K
    Blood Adv; 2023 Sep; 7(17):4903-4912. PubMed ID: 36661315
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I/II study of pralatrexate in Japanese patients with relapsed or refractory peripheral T-cell lymphoma.
    Maruyama D; Nagai H; Maeda Y; Nakane T; Shimoyama T; Nakazato T; Sakai R; Ishikawa T; Izutsu K; Ueda R; Tobinai K
    Cancer Sci; 2017 Oct; 108(10):2061-2068. PubMed ID: 28771889
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A phase I clinical trial of darinaparsin in patients with refractory solid tumors.
    Tsimberidou AM; Camacho LH; Verstovsek S; Ng C; Hong DS; Uehara CK; Gutierrez C; Daring S; Stevens J; Komarnitsky PB; Schwartz B; Kurzrock R
    Clin Cancer Res; 2009 Jul; 15(14):4769-76. PubMed ID: 19584162
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A multicenter phase II study of darinaparsin in relapsed or refractory Hodgkin's and non-Hodgkin's lymphoma.
    Hosein PJ; Craig MD; Tallman MS; Boccia RV; Hamilton BL; Lewis JJ; Lossos IS
    Am J Hematol; 2012 Jan; 87(1):111-4. PubMed ID: 22081459
    [No Abstract]   [Full Text] [Related]  

  • 6. [Pharmacological profile and clinical study results of darinaparsin (DARVIAS
    Yao K; Sonehara Y; Nagahama F
    Nihon Yakurigaku Zasshi; 2023; 158(5):408-418. PubMed ID: 37673618
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Japanese subgroup analysis in the Asian phase II study of darinaparsin in patients with relapsed or refractory peripheral T-cell lymphoma.
    Negoro E; Yamauchi T; Fukuhara N; Yamamoto K; Uchida T; Izutsu K; Maruyama D; Terui Y; Nakajima H; Ando K; Suehiro Y; Choi I; Kanemura N; Nakamura N; Yamamoto G; Maeda Y; Shibayama H; Nagahama F; Sonehara Y; Nagai H; Tien HF; Kwong YL; Kim WS; Tobinai K
    J Clin Exp Hematop; 2023; 63(2):108-120. PubMed ID: 37380467
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Polatuzumab vedotin plus obinutuzumab and lenalidomide in patients with relapsed or refractory follicular lymphoma: a cohort of a multicentre, single-arm, phase 1b/2 study.
    Diefenbach C; Kahl BS; McMillan A; Briones J; Banerjee L; Cordoba R; Miall F; Burke JM; Hirata J; Jiang Y; Paulson JN; Chang YM; Musick L; Abrisqueta P
    Lancet Haematol; 2021 Dec; 8(12):e891-e901. PubMed ID: 34826412
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase II study of darinaparsin in patients with advanced hepatocellular carcinoma.
    Wu J; Henderson C; Feun L; Van Veldhuizen P; Gold P; Zheng H; Ryan T; Blaszkowsky LS; Chen H; Costa M; Rosenzweig B; Nierodzik M; Hochster H; Muggia F; Abbadessa G; Lewis J; Zhu AX
    Invest New Drugs; 2010 Oct; 28(5):670-6. PubMed ID: 19565187
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Panobinostat in combination with bortezomib in patients with relapsed or refractory peripheral T-cell lymphoma: an open-label, multicentre phase 2 trial.
    Tan D; Phipps C; Hwang WY; Tan SY; Yeap CH; Chan YH; Tay K; Lim ST; Lee YS; Kumar SG; Ng SC; Fadilah S; Kim WS; Goh YT;
    Lancet Haematol; 2015 Aug; 2(8):e326-33. PubMed ID: 26688485
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Romidepsin in Japanese patients with relapsed or refractory peripheral T-cell lymphoma: a phase I/II and pharmacokinetics study.
    Maruyama D; Tobinai K; Ogura M; Uchida T; Hatake K; Taniwaki M; Ando K; Tsukasaki K; Ishida T; Kobayashi N; Ishizawa K; Tatsumi Y; Kato K; Kiguchi T; Ikezoe T; Laille E; Ro T; Tamakoshi H; Sakurai S; Ohtsu T
    Int J Hematol; 2017 Nov; 106(5):655-665. PubMed ID: 28664499
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and efficacy of tenalisib in combination with romidepsin in patients with relapsed/refractory T-cell lymphoma: results from a phase I/II open-label multicenter study.
    Iyer SP; Huen A; Ai WZ; Jagadeesh D; Lechowicz MJ; Okada C; Feldman TA; Ghione P; Alderuccio JP; Champion R; Kim SH; Mohrbacher A; Routhu KV; Barde P; Nair AM; Haverkos BM
    Haematologica; 2024 Jan; 109(1):209-219. PubMed ID: 37439343
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Golidocitinib, a selective JAK1 tyrosine-kinase inhibitor, in patients with refractory or relapsed peripheral T-cell lymphoma (JACKPOT8 Part B): a single-arm, multinational, phase 2 study.
    Song Y; Malpica L; Cai Q; Zhao W; Zhou K; Wu J; Zhang H; Mehta-Shah N; Ding K; Liu Y; Li Z; Zhang L; Zheng M; Jin J; Yang H; Shuang Y; Yoon DH; Gao S; Li W; Zhai Z; Zou L; Xi Y; Koh Y; Li F; Prince M; Zhou H; Lin L; Liu H; Allen P; Roncolato F; Yang Z; Kim WS; Zhu J
    Lancet Oncol; 2024 Jan; 25(1):117-125. PubMed ID: 38092009
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Results from a multicenter, open-label, pivotal phase II study of chidamide in relapsed or refractory peripheral T-cell lymphoma.
    Shi Y; Dong M; Hong X; Zhang W; Feng J; Zhu J; Yu L; Ke X; Huang H; Shen Z; Fan Y; Li W; Zhao X; Qi J; Huang H; Zhou D; Ning Z; Lu X
    Ann Oncol; 2015 Aug; 26(8):1766-71. PubMed ID: 26105599
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The novel organic arsenical darinaparsin induces MAPK-mediated and SHP1-dependent cell death in T-cell lymphoma and Hodgkin lymphoma cells and human xenograft models.
    Ravi D; Bhalla S; Gartenhaus RB; Crombie J; Kandela I; Sharma J; Mazar A; Evens AM
    Clin Cancer Res; 2014 Dec; 20(23):6023-33. PubMed ID: 25316819
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pralatrexate in patients with relapsed or refractory peripheral T-cell lymphoma: results from the pivotal PROPEL study.
    O'Connor OA; Pro B; Pinter-Brown L; Bartlett N; Popplewell L; Coiffier B; Lechowicz MJ; Savage KJ; Shustov AR; Gisselbrecht C; Jacobsen E; Zinzani PL; Furman R; Goy A; Haioun C; Crump M; Zain JM; Hsi E; Boyd A; Horwitz S
    J Clin Oncol; 2011 Mar; 29(9):1182-9. PubMed ID: 21245435
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phase II study on the role of gemcitabine plus romidepsin (GEMRO regimen) in the treatment of relapsed/refractory peripheral T-cell lymphoma patients.
    Pellegrini C; Dodero A; Chiappella A; Monaco F; Degl'Innocenti D; Salvi F; Vitolo U; Argnani L; Corradini P; Zinzani PL;
    J Hematol Oncol; 2016 Apr; 9():38. PubMed ID: 27071522
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lenalidomide in relapsed adult T-cell leukaemia-lymphoma or peripheral T-cell lymphoma (ATLL-001): a phase 1, multicentre, dose-escalation study.
    Ogura M; Imaizumi Y; Uike N; Asou N; Utsunomiya A; Uchida T; Aoki T; Tsukasaki K; Taguchi J; Choi I; Maruyama D; Nosaka K; Chen N; Midorikawa S; Ohtsu T; Tobinai K
    Lancet Haematol; 2016 Mar; 3(3):e107-18. PubMed ID: 26947199
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Combination of romidepsin with cyclophosphamide, doxorubicin, vincristine, and prednisone in previously untreated patients with peripheral T-cell lymphoma: a non-randomised, phase 1b/2 study.
    Dupuis J; Morschhauser F; Ghesquières H; Tilly H; Casasnovas O; Thieblemont C; Ribrag V; Bossard C; Le Bras F; Bachy E; Hivert B; Nicolas-Virelizier E; Jardin F; Bastie JN; Amorim S; Lazarovici J; Martin A; Coiffier B
    Lancet Haematol; 2015 Apr; 2(4):e160-5. PubMed ID: 26687958
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Avadomide plus obinutuzumab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma (CC-122-NHL-001): a multicentre, dose escalation and expansion phase 1 study.
    Michot JM; Bouabdallah R; Vitolo U; Doorduijn JK; Salles G; Chiappella A; Zinzani PL; Bijou F; Kersten MJ; Sarmiento R; Mosulen S; Mendez C; Uttamsingh S; Pourdehnad M; Hege K; Chen T; Klein C; Hagner PR; Nikolova Z; Ribrag V
    Lancet Haematol; 2020 Sep; 7(9):e649-e659. PubMed ID: 32758434
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.